Watch SLN. Know when insiders buy.
One email the day a filing lands. Free.
SLN
Silence Therapeutics plc
19.83
+0.03 +0.15%
USD · close Nov 13
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.8BP/E —DIV YIELD —FCF YIELD -1.50%REV TTM $615K −97.7%NET INCOME −$60MNET CASH —52W 4.30 – 19.83SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q 2026 · Jun 30 | $0 | −100.0% | — | −$13.9M | −$12.3M | — | -0.09 | $1.5M | $0 | $1.5M | Aug 10 |
| Q 2026 · Mar 31 | $422K | +197.2% | 97.4% | −$15.7M | −$15M | — | -0.11 | −$15.6M | $0 | −$15.6M | Aug 10 |
| Q 2025 · Dec 31derived | $34K | −99.9% | 64.7% | −$12.5M | −$11.8M | −195.7% | -0.09 | −$17.3M | $0 | −$17.3M | Mar 5 |
| Q 2025 · Sep 30 | $159K | −89.4% | 59.7% | −$26.2M | −$21M | — | -0.15 | −$10.9M | $3K | −$10.9M | Nov 6 |
| Q 2025 · Jun 30 | $224K | −70.4% | 62.1% | −$24M | −$27.4M | — | -0.19 | −$21.8M | $48K | −$21.8M | Aug 10 |
| Q 2025 · Mar 31 | $142K | −99.1% | 62.0% | −$28.4M | −$28.5M | — | -0.20 | −$12.3M | $4K | −$12.3M | Aug 10 |
| Q 2024 · Dec 31derived | $25.3M | — | 91.9% | −$4.4M | $12.3M | — | 0.09 | −$27.5M | $62K | −$27.5M | Mar 5 |
| Q 2024 · Sep 30 | $1.5M | — | -142.9% | −$30M | −$35.5M | — | -0.25 | −$25.6M | $64K | −$25.7M | Nov 6 |
| Q 2024 · Jun 30 | $756K | — | -340.9% | −$23.4M | −$19.8M | — | -0.14 | −$5.4M | $85K | −$5.5M | Nov 6 |
| Q 2024 · Mar 31 | $15.7M | — | 82.2% | −$5.6M | −$2.3M | — | -0.02 | −$9.1M | $0 | −$9.1M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $559K | 61.5% | −$91.1M | −$88.6M | -15851.9% | -0.63 | −$62.3M | $55K | −$62.3M | — | — |
| FY2024 · to Dec 31 | $43.3M | 72.7% | −$63.3M | −$45.3M | -104.7% | -0.33 | −$67.6M | $211K | −$67.9M | — | — |
| FY2023 · to Dec 31 | $31.6M | 59.3% | −$64.4M | −$54.2M | -171.4% | -0.49 | −$49.5M | $56K | −$49.5M | — | — |
| FY2022 · to Dec 31 | $21.7M | 37.8% | −$61M | −$50.3M | -232.4% | -0.52 | −$57M | $173K | −$57.2M | — | — |
Every number comes from Silence Therapeutics plc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.